H K E C S E H K L

FOSUN PHARMA

復星醫藥

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(P R C)

(Stock Code: 02196)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

FINANCIAL HIGHLIGHTS

	2023	
	RMB	*RMB*
Operating results		
	41,249	
	19,653	
	1,100	
	7,720	
	3,277	
	2,399	
Profitability		
	47.64%	
	7.05%	
Earnings per share (RMB Yuan)		
	0.90	
	0.90	
Assets		
	113,431	
	45,646	
	56,853	

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

[illegible] 31 D[illegible] 2023

	N[illegible]	2023 *RMB'000*	[illegible] *RMB'000*
REVENUE	*3*	**41,248,505**	[illegible]
[illegible]		**(21,595,309)**	[illegible]
[illegible]		**19,653,196**	[illegible]
[illegible]	*4*	**524,980**	[illegible]
[illegible]		**(9,712,237)**	[illegible]
[illegible]		**(4,495,128)**	[illegible]
[illegible]		**(131,927)**	[illegible]
[illegible]		**(4,346,045)**	[illegible]
[illegible]	*6*	**1,392,007**	[illegible]
[illegible]		**(831,601)**	[illegible]
[illegible]		**363,645**	[illegible]
[illegible]	*7*	**(1,324,831)**	[illegible]
[illegible]		**(202,030)**	[illegible]
[illegible]		**2,386,879**	[illegible]
PROFIT BEFORE TAX	*5*	**3,276,908**	[illegible]
[illegible]	*8*	**(369,504)**	[illegible]
PROFIT FOR THE YEAR		**2,907,404**	[illegible]
[illegible]		**2,398,606**	[illegible]
[illegible]		**508,798**	[illegible]
		2,907,404	[illegible]
[illegible]	*10*		
[illegible]		**RMB0.90**	[illegible]
[illegible]		**RMB0.90**	[illegible]

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

[illegible] 31 D[illegible] 2023

	2023	[illegible]
	RMB'000	*RMB'000*
PROFIT FOR THE YEAR	**2,907,404**	[illegible]
OTHER COMPREHENSIVE INCOME		
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

	2023	
	RMB'000	*RMB'000*
NON-CURRENT LIABILITIES		
[illegible]	**13,504,923**	[illegible]
[illegible]	**2,049,589**	[illegible]
[illegible]	**3,445,191**	[illegible]
[illegible]	**319,785**	[illegible]
[illegible]	**639,399**	[illegible]
[illegible]	**3,136,874**	[illegible]
[illegible]	**23,095,761**	[illegible]
[illegible]	**56,577,885**	[illegible]
EQUITY		
Equity attributable to owners of the parent		
[illegible]	**2,672,399**	[illegible]
[illegible]	**(41,928)**	[illegible]
[illegible]	**43,015,915**	[illegible]
	45,646,386	[illegible]
Non-controlling interests	**10,931,499**	[illegible]
[illegible]	**56,577,885**	[illegible]

1.1 BASIS OF PREPARATION

[illegible] "HKFRSs" [illegible] "HKASs" [illegible] "HKICPA" [illegible] "RMB" [illegible]

Basis of consolidation

[illegible] "Group" [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

1.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

[illegible]

I C

D A P

D A E

D T A L S T

I T R — P T M R

[illegible]

M M J

[illegible]

D T A L S T

[illegible]

I T R — P T M R

[illegible]

[illegible]

1.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS

[illegible]

[illegible]

[illegible]

Year ended 31 December 2023

	Pharma-ceutical manufacturing *RMB'000*	Medical devices and medical diagnosis *RMB'000*	Healthcare Service *RMB'000*	Pharma-ceutical distribution and retail *RMB'000*	Others *RMB'000*	Eliminations *RMB'000*	Total *RMB'000*
[illegible]	30,080,246	4,386,495	6,667,137	—	114,627	—	41,248,505
[illegible]	470,731	54,063	42,866	—	35,726	(603,386)	—
[illegible]	30,550,977	4,440,558	6,710,003	—	150,353	(603,386)	41,248,505
[illegible]	2,133,620	(126,443)	(200,661)	—	(80,398)	(119,758)	1,606,360
[illegible]	342,065	56,167	49,453	—	49,415	—	497,100
[illegible]	329,170	56	23,039	—	149,667	—	501,932
[illegible]	235,169	30,611	24,260	—	2,615	(23,896)	268,759
[illegible]	(254,032)	(34,398)	(245,598)	—	(44,186)	133,272	(444,942)
[illegible]	(288,780)	(93,932)	(65,354)	—	(1,002)	1,173	(447,895)
[illegible]	(209,238)	—	(1,376)	—	8,584	—	(202,030)
[illegible]	27,365	128,527	1,427	2,242,195	(12,635)	—	2,386,879
[illegible]							(889,255)
[illegible]	2,315,339	(39,412)	(414,810)	2,242,195	72,060	(9,209)	3,276,908
[illegible]	(341,571)	6,666	(25,005)	—	(6,189)	—	(366,099)
[illegible]							(3,405)
[illegible]	1,973,768	(32,746)	(439,815)	2,242,195	65,871	(9,209)	2,907,404
[illegible]	60,228,777	10,328,867	15,575,622	18,972,525	5,096,173	(2,997,488)	107,204,476
[illegible]	67,249	—	—	—	11,661	—	78,910
[illegible]	505,797	1,483,895	688,591	18,972,525	2,151,305	—	23,802,113
[illegible]							6,226,751
[illegible]							113,431,227
[illegible]	24,081,873	2,672,929	7,609,566	—	2,077,696	(13,666,779)	22,775,285
[illegible]							34,078,057
[illegible]							56,853,342
[illegible]	2,186,643	369,461	532,164	—	114,485	—	3,202,753
[illegible]	224,224	82,804	53,055	—	—	—	360,083
[illegible]							(8,414)
[illegible]	4,470,575	551,519	602,539	—	133,195	—	5,757,828

Year ended 31 December 2022

	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Revenue from contracts with customers

(i) ***D a e a ed e e e a***

For the year ended 31 December 2023

Segments	Pharmaceutical manufacturing *RMB'000*	Medical devices and medical diagnosis *RMB'000*	Healthcare Service *RMB'000*	Pharmaceutical distribution and retail *RMB'000*	Others *RMB'000*	Total *RMB'000*
Type of goods or services						
[illegible]	28,532,071	4,245,408	686,595	—	32,949	33,497,023
[illegible]	1,517,980	127,270	5,976,603	—	33,450	7,655,303
[illegible]	22,320	11,258	—	—	—	33,578
[illegible]	30,072,371	4,383,936	6,663,198	—	66,399	41,185,904
Geographical markets						
[illegible]	22,629,786	1,466,935	6,654,040	—	64,528	30,815,289
[illegible]	7,442,585	2,917,001	9,158	—	1,871	10,370,615
[illegible]	30,072,371	4,383,936	6,663,198	—	66,399	41,185,904
[illegible]	28,554,391	4,256,666	686,595	—	32,949	33,530,601
[illegible]	1,205,727	34,162	5,976,603	—	33,450	7,249,942
[illegible]	312,253	93,108	—	—	—	405,361
[illegible]	30,072,371	4,383,936	6,663,198	—	66,399	41,185,904

For the year ended 31 December 2022

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
Type of goods or services						
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	—	—	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
Geographical markets						
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	—	—	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]

[illegible]

	2023	[illegible]
	RMB'000	*RMB'000*
[illegible]		
[illegible]	**1,493,312**	[illegible]
[illegible]	**51,450**	[illegible]
	1,544,762	[illegible]

(ii) ***Pe a ce b a***

S

R

	2023	
	RMB'000	*RMB'000*
	1,200,496	
	319,785	
	1,520,281	

4. OTHER INCOME

	2023	
	RMB'000	*RMB'000*
	61,239	
	203	
	463,538	
	—	
	524,980	

5. PROFIT BEFORE TAX

[illegible]

	2023	[illegible]
	RMB'000	*RMB'000*
[illegible]	16,189,857	[illegible]
[illegible]	5,405,452	[illegible]
[illegible]		
[illegible]	9,322,174	[illegible]
[illegible]	553,831	[illegible]
[illegible]	328,098	[illegible]
[illegible]	35,898	[illegible]
	10,240,001	[illegible]
[illegible]		
[illegible]	3,877,623	[illegible]
[illegible]	(56,687)	[illegible]
	3,820,936	[illegible]
[illegible]	4,660	[illegible]
[illegible]	1,517,737	[illegible]
[illegible]	1,282,683	[illegible]
[illegible]	2,408	[illegible]
[illegible]	121,339	[illegible]
[illegible]	131,927	[illegible]
[illegible]	—	[illegible]
[illegible]	21,592	[illegible]
[illegible]	61,284	—
[illegible]	13,119	—
[illegible]	318,258	[illegible]
[illegible]	113,749	[illegible]
[illegible]	(558,489)	[illegible]
[illegible]	(47,204)	[illegible]
[illegible]	452,384	[illegible]
[illegible]	(710,599)	[illegible]
[illegible]	(13,027)	[illegible]
[illegible]	1,046	[illegible]
[illegible]	(538)	[illegible]
[illegible]	45,909	[illegible]

[illegible]

[illegible] "Phixen" [illegible]

	2023	[illegible]
	RMB'000	*RMB'000*
[illegible]	529,206	[illegible]
[illegible]	(159,702)	[illegible]
[illegible]	369,504	[illegible]

9. DIVIDENDS

Cash dividend

	2023	[illegible]
	RMB'000	*RMB'000*
[illegible]	721,548	[illegible]

[illegible]

[illegible]

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

[illegible]

[illegible]

	2023	[illegible]
	RMB'000	*RMB'000*
Earnings		
[illegible]	**2,398,606**	[illegible]
[illegible]	**(1,050)**	—
[illegible]	**2,397,556**	[illegible]
[illegible]	**1,050**	—
[illegible]	**2,398,606**	[illegible]

	Number of shares	
	2023	[illegible]
Shares		
[illegible]	**2,669,655,211**	[illegible]
[illegible]	**253,150**	[illegible]
	2,669,908,361*	[illegible]

[illegible]

11. TRADE AND BILLS RECEIVABLES

	2023	
	RMB'000	*RMB'000*
[illegible]	7,643,737	[illegible]
[illegible]	24,492	[illegible]
	7,668,229	[illegible]

[illegible]

[illegible]

	2023	
	RMB'000	*RMB'000*
[illegible]	7,436,979	[illegible]
[illegible]	333,408	[illegible]
[illegible]	77,594	[illegible]
[illegible]	64,952	[illegible]
	7,912,933	[illegible]
[illegible]	(269,196)	[illegible]
	7,643,737	[illegible]

12. TRADE AND BILLS PAYABLES

	2023	
	RMB'000	*RMB'000*
[illegible]	5,507,366	[illegible]
[illegible]	652,253	[illegible]
	6,159,619	[illegible]

[illegible]

	2023	[illegible]
	RMB'000	*RMB'000*
[illegible]	**5,191,820**	[illegible]
[illegible]	**223,314**	[illegible]
[illegible]	**57,124**	[illegible]
[illegible]	**35,108**	[illegible]
	5,507,366	[illegible]

13. EVENTS AFTER THE REPORTING PERIOD

[illegible]

MANAGEMENT DISCUSSION AND ANALYSIS

THE BOARD'S DISCUSSION AND ANALYSIS ON OPERATIONS OF THE GROUP FOR THE REPORTING PERIOD

	2023 revenue		[illegible]	[illegible]
	Amount	Percentage of revenue (%)	[illegible] (%)	[illegible] (%)
By business segment				
[illegible] *Note 1*	**30,080**	**72.92**	[illegible]	[illegible]
[illegible] *Note 2*	**4,386**	**10.63**	[illegible]	[illegible]
[illegible]	**6,667**	**16.16**	[illegible]	[illegible]
By geographical locations				
[illegible]	**30,878**	**74.86**	[illegible]	[illegible]
[illegible]	**10,371**	**25.14**	[illegible]	[illegible] *Note 3*

Note 1: [illegible]

Note 2: [illegible]

Note 3: [illegible]

I. MAIN OPERATIONAL PROGRESS OF THE GROUP DURING THE REPORTING PERIOD

1. Continued to promote the innovation transformation and the development and launch of innovative products

[illegible]

2. Continued to enhance global operation capabilities

- *I e a a a e a e d c*

[illegible]

- ***P e ba - a ce e c e a***

[illegible]

- ***P e b d d c e e a a a a da d***

[illegible]

[illegible]

3. Continued to strengthen business focus by product lines and enhance efficiency through integration

[illegible]

[illegible]

4. Matured commercialization system

[illegible]

5. Digitally empowered business continued to grow

[illegible]

[illegible]



Progress during the Reporting Period	Drug name/code	Target/mechanism	Drug Category	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
	[illegible]	[illegible]	[illegible]	[illegible]						[illegible]
	[illegible]		[illegible]	[illegible]						—

[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

Table 2: Major marketed innovative products and description of core categories

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]		

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	

* B [illegible] ([illegible]) [illegible] G [illegible].

II. SEGMENT PERFORMANCE OVERVIEW

1. Pharmaceutical manufacturing

Pe a ce a

[illegible]

[illegible] ①

Major therapeutic area	2023	[illegible]	[illegible] (%)
[illegible] (N [illegible] 1, 5)	**7,638**	[illegible]	[illegible]
[illegible] (N [illegible] 2, 5)	**4,340**	[illegible]	[illegible]
[illegible] (N [illegible] 5)	**2,824**	[illegible]	[illegible]
[illegible] (N [illegible] 3, 5)	**1,677**	[illegible]	[illegible]
[illegible] (N [illegible] 4, 5)	**1,184**	[illegible]	[illegible]
[illegible] (N [illegible] 5)	**1,271**	[illegible]	[illegible]

N [illegible] 1: [illegible]

N [illegible] 2: [illegible]

N [illegible] 3: [illegible]

N [illegible] 4: [illegible]

N [illegible] 5: [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Sales during the Reporting Period	Number	Preparation varieties or series
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

I a e e

- *T (PD-1)*

[illegible]

[illegible]

- *A [illegible] CAR-T [illegible]*

[illegible]

[illegible]

[illegible]

[illegible]

- *P* [illegible]

[illegible]

《藥品生產許可證》

《藥品經營許可證》

力妥寧

R&D a

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]



No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—

N [illegible]

Table 5 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in major licensed territory as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]

No.	Therapeutic area	Drug name/code	Indications	R&D progress in major licensed territory as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

Table 6 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese mainland as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
			[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N [illegible]

[illegible]

— [illegible]

Table 7 — Products won tenders for centralized procurement

No.	Round selected	Name of drugs	Indications	Specifications	Charge unit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]

No.	Round selected	Name of drugs	Indications	Specifications	Charge unit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

2. Medical Devices and Medical Diagnosis

Medical Device



“Ion System”

[illegible]

Med ca D a

[illegible]

4. Pharmaceutical Distribution and Retail

[illegible]

[illegible]

[illegible]

[illegible]

5. Financing

[illegible]

[illegible]

III. CORE COMPETENCE ANALYSIS

[illegible]

[illegible]

[illegible]

[illegible]

IV. MAJOR OPERATIONS IN THE REPORTING PERIOD

(I) Analysis on Principal Operations

1. *A a C a e Ree a I e I c e S a e e a d S a e e Ca F*

[illegible]

Items	Amount for the year	Amount for last year	Year-on-year change	R
[illegible]	[illegible]	[illegible]	[illegible]	N 1
[illegible]	[illegible]	[illegible]	[illegible]	N 1
[illegible]	[illegible]	[illegible]	[illegible]	N 2
[illegible]	[illegible]	[illegible]	[illegible]	N 3
[illegible]	[illegible]	[illegible]	[illegible]	N 4
[illegible]	[illegible]	[illegible]	[illegible]	N 5
[illegible]	[illegible]	[illegible]	[illegible]	N 5
[illegible]	[illegible]	[illegible]	[illegible]	N 6
[illegible]	[illegible]	[illegible]	[illegible]	N 7

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

N 6: [illegible]

N 7: [illegible]

2. *A a [illegible] Re e e a d C [illegible] Sa e*

P [illegible] O [illegible] S [illegible], P [illegible], G [illegible] L [illegible]

[illegible]

			Principal Operations by Segments			
By segments	**Revenue**	**Cost of sales**	**Gross profit margin** *(%)*	**Year-on-year change in revenue** *(%)*	**Year-on-year change in cost of sales** *(%)*	**Year-on-year change in gross margin**
[illegible]	[illegible]	[illegible]	[illegible]	–(%)	2488298.4(13382.5(485((-6.5N)63(	

Principal Operations by Products

By products	Revenue	Cost of sales	Gross profit margin (%)	Year-on-year change in revenue (%)	Year-on-year change in cost of sales (%)	Year-on-year change in gross margin
[illegible] (Note 2)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (Note 3)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Principal Operations by Geographical Locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Year-on-year change in revenue (%)	Year-on-year change in cost of sales (%)	Year-on-year change in gross margin
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (Note 4)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Note 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

[illegible] *A* [illegible] *P* [illegible]

Major products	Unit	Production volume	Sales volume	Inventory	Year-on-year change in production volume (%)	Year-on-year change in sales volume (%)	Year-on-year change in inventory (%)
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N : [illegible]

By Segments

By Segments	Cost	Amount for the period	Percentage of the total cost for the period (%)	Amount for the corresponding period of last year	Percentage of the total cost for the corresponding period of last year (%)	Ratio of change for the period as compared with the corresponding period of last year (%)
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 1)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

By Products

By Products	Cost	Amount for the period	Percentage of the total cost for the period (%)	Amount for the corresponding period of last year	Percentage of the total cost for the corresponding period of last year (%)	Ratio of change for the period as compared with the corresponding period of last year (%)
[illegible] (N 2)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 3)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 4)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

M C S

[illegible]

[illegible]

3. *E e e*

[illegible]

4. ***R&D E e d e***

A R&D

藥品註冊管理辦法

R&D Expenditures

D

5. ***Ca F***

Items	Amount for the period	Amount for the corresponding period of last year	Ratio of change *(%)*	Reasons

(II) Assets and liabilities analysis

[illegible]

Assets and liabilities

[illegible]

Items	Amount as at the end of the period	Percentage of the amount as at the end of the period to the total asset *(%)*	Amount as at the end of last period	Percentage of the amount as at the end of last period to the total assets *(%)*	Ratio of change for the amount as at the end of the period as compared with the amount as at the end of last period *(%)*	Reasons
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	—	—	[illegible]	[illegible]
[illegible]	—	—	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

N 6: [illegible]

N 7: [illegible]

N 8: [illegible]

N 9: [illegible]

N 10: [illegible]

(III) Analysis on Subsidiaries and Investees

O R M S G

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 1)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 2)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N : [illegible]

N 1: [illegible]

N 2: [illegible]

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Net profit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

O R I C P C I
I M T 10% G ' N P

Name of company	Principal activities	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

A D S R P (
P , M E A D E
G ' O O R)

Name	Acquired through	Date of acquisition/merger
[illegible]	[illegible]	[illegible]

Name	Disposed through	Date of disposal

Note:

(IV) Employees and Remuneration Policies

THE BOARD'S DISCUSSION AND ANALYSIS ON FUTURE DEVELOPMENT OF THE GROUP

I. Industry Landscape and Trends

II. Corporate Development Strategies

III. Operation Plan

P a ace ca Ma ac

Medical Devices and Medical Data

[illegible]

Healthcare Service

[illegible]

P a ace ca D b a d Re a

F a c

IV. Potential Risks

(I) Industry policies adjustments

[illegible]

[illegible]

[illegible]

(II) Market risks

[illegible]

[illegible]

[illegible]

[illegible]

(III) Business and operating risks

[illegible] *R&D* [illegible]

[illegible]

[illegible] *C* [illegible] / [illegible]

[illegible]

(IV) Management risks

R

R

(V) Foreign exchange risks

[illegible]

[illegible]

(VI) Force majeure risks

[illegible]

[illegible]

OTHER EVENTS

I. Approval for Registration of Corporate Bonds by the CSRC

[illegible] "Approval" [illegible]

III. Increase in Shareholding by a Controlling Shareholder

[illegible]

"Shareholding Increase Plan" [illegible]

[illegible]

IV. 2022 Restricted A Share Incentive Scheme

[illegible]

[illegible]

V. 2022 H Share Employee Share Ownership Scheme

REPURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

2022 Restricted A Share Incentive Scheme

[illegible]

[illegible]

Sell back of "21 Fosun 01" Corporate Bonds

[illegible]"21 Fosun 01"[illegible]復藥[illegible]"[illegible]"《上海復星醫藥([illegible]團)股份有[illegible]公司[illegible]年公開發行公司債券(第一期)募[illegible]說明書(面向專業投[illegible]者)》[illegible]

[illegible]

COMPLIANCE WITH THE CG CODE

[illegible]

[illegible]

PUBLICATION OF ANNUAL RESULTS AND ANNUAL REPORT

DEFINITIONS

錦州奧鴻藥業有

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]美中互利北京國[illegible]易有[illegible]公司[illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]上海復星醫藥團股份有[illegible]公司[illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]中國證券監督管理委員會

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]佛山復星禪誠醫[illegible]有公司[illegible]

“[illegible]” [illegible]復星[illegible]立峰大連[illegible]生[illegible]製藥有[illegible]公司[illegible]

“[illegible]” [illegible]復星安[illegible]金成都[illegible]生[illegible]製藥有[illegible]公司[illegible]

“[illegible]” [illegible]上海復星高科技[illegible]團[illegible]有[illegible]公司[illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]復星凱[illegible]生[illegible]科技有公司[illegible]

“[illegible]” [illegible]上海復拓知達醫療科技有[illegible]公司[illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]廣州新市醫[illegible]有[illegible]公司[illegible]

“[illegible]” [illegible]桂[illegible]南藥股份有[illegible]公司[illegible]

“[illegible]” [illegible]

“[illegible]” [illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]湖南洞庭藥業股份有[illegible]公司[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]直觀復星醫療[illegible]械技術(上海)有[illegible]公司[illegible]

“[illegible]”[illegible]醫療投[illegible]管理有[illegible]公司[illegible]國藥控股醫療投[illegible]管理有[illegible]公司[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]

“[illegible]”[illegible]《國家基[illegible]醫療保[illegible]、工[illegible]保和生育保[illegible]藥品目錄》[illegible]

“[illegible]”	[illegible] 中國國家藥品監督管理局
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]” and “[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible] 上海復宏漢霖生□技術股份有 公司 [illegible]
“[illegible]”	[illegible] 上海證券交易所
“[illegible]”	[illegible] 上海星晨兒童醫 有 公司 [illegible]
“[illegible]”	[illegible] 上海曜康醫藥科技有 公司 [illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible]
“[illegible]”	[illegible] 重慶星 整 形 科醫 有 □任公司 [illegible]

"[illegible]"	[illegible]國藥控股股份有[illegible]公司([illegible]
"[illegible]"	[illegible]國藥產業投[illegible]有[illegible]公司([illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]" "[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"/[illegible]"	[illegible]江蘇萬邦生化醫藥[illegible]團有[illegible]任公司([illegible]
"/[illegible]"	[illegible]
"/[illegible]"	[illegible]
"/[illegible]"	[illegible]《上海復星醫藥[illegible]團(股份有[illegible]公司董事／有關[illegible]員進行證券交易的書面守則》(
"[illegible]"	[illegible]江蘇星諾醫藥科技有[illegible]公司([illegible]
"[illegible]"	[illegible]廣州市心怡堂大藥房有公司([illegible]
"[illegible]"	[illegible]徐州萬邦[illegible]藥房連鎖有[illegible]公司([illegible]
"[illegible]"	[illegible]徐州星晨婦兒醫[illegible]有[illegible]公司([illegible]

“ ”

“ ”

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
C

A , C M . W , M . W K , M . G M . W D ; - C M . C Q , M . F , M . M . P D ; - C M . L L , M . T G , M . W Q M . T S H .

F